You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
If approved, the drug would be the first targeted therapy available to treat patients with NSCLC harboring KRAS G12C mutations.
Sema4 will use its next-generation sequencing testing services to identify patients with solid tumors harboring NRG1 fusions for Merus' Phase I/II drug trial.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The study is evaluating the drug in previously treated NSCLC patients with alterations in EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET.
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The agency recommended the drug based on the results from the Phase III ALTA-1L trial, and after Takeda agreed to offer the drug to NHS England at a discount.
Persephone Biosciences has launched a prospective, longitudinal study to evaluate 4,000 patients' gut microbiomes and link them with cancer treatment response.
Janssen's biologics license application for amivantamab is the first regulatory submission for a drug to target lung cancer patients with EGFR exon 20 mutations.
The Phase I/II clinical trial will evaluate Genprex's Reqorsa and AstraZeneca's Tagrisso in patients with EGFR-mutated non-small cell lung cancer.
The firm will collect stool and blood samples from 4,000 cancer patients and determine whether their microbiome composition affects their response to therapy.